Free Trial
NASDAQ:KYTX

Kyverna Therapeutics (KYTX) Stock Price, News & Analysis

Kyverna Therapeutics logo
$3.11 +0.29 (+10.28%)
Closing price 04:00 PM Eastern
Extended Trading
$3.16 +0.05 (+1.61%)
As of 06:14 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Kyverna Therapeutics Stock (NASDAQ:KYTX)

Key Stats

Today's Range
$2.78
$3.15
50-Day Range
$2.02
$3.60
52-Week Range
$1.78
$11.40
Volume
692,161 shs
Average Volume
384,840 shs
Market Capitalization
$134.41 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.50
Consensus Rating
Buy

Company Overview

Kyverna Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
34th Percentile Overall Score

KYTX MarketRank™: 

Kyverna Therapeutics scored higher than 34% of companies evaluated by MarketBeat, and ranked 811th out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Kyverna Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.14, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Kyverna Therapeutics has only been the subject of 1 research reports in the past 90 days.

  • Read more about Kyverna Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Kyverna Therapeutics are expected to decrease in the coming year, from ($3.29) to ($3.73) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Kyverna Therapeutics is -0.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Kyverna Therapeutics is -0.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Kyverna Therapeutics has a P/B Ratio of 0.50. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Kyverna Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    10.79% of the float of Kyverna Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Kyverna Therapeutics has a short interest ratio ("days to cover") of 6.3.
  • Change versus previous month

    Short interest in Kyverna Therapeutics has recently increased by 0.48%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Kyverna Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Kyverna Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    10.79% of the float of Kyverna Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Kyverna Therapeutics has a short interest ratio ("days to cover") of 6.3.
  • Change versus previous month

    Short interest in Kyverna Therapeutics has recently increased by 0.48%, indicating that investor sentiment is decreasing.
  • Search Interest

    Only 1 people have searched for KYTX on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.
  • MarketBeat Follows

    2 people have added Kyverna Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Kyverna Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    22.00% of the stock of Kyverna Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 18.08% of the stock of Kyverna Therapeutics is held by institutions.

  • Read more about Kyverna Therapeutics' insider trading history.
Receive KYTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kyverna Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

KYTX Stock News Headlines

Top Picks for Trump’s Pro-Crypto America
Mark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…
3 Promising Penny Stocks With Market Caps Over $100M
See More Headlines

KYTX Stock Analysis - Frequently Asked Questions

Kyverna Therapeutics' stock was trading at $3.74 at the beginning of 2025. Since then, KYTX stock has decreased by 16.8% and is now trading at $3.11.

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) announced its quarterly earnings data on Tuesday, May, 13th. The company reported ($1.03) EPS for the quarter, topping analysts' consensus estimates of ($1.21) by $0.18.

Kyverna Therapeutics (KYTX) raised $319 million in an initial public offering on Thursday, February 8th 2024. The company issued 14,500,000 shares at $22.00 per share.

Top institutional investors of Kyverna Therapeutics include Kera Capital Partners Inc. (0.98%).
View institutional ownership trends
.

Shares of KYTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Kyverna Therapeutics investors own include Tesla (TSLA), NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Alphabet (GOOG).

Company Calendar

Last Earnings
5/13/2025
Today
7/09/2025
Next Earnings (Estimated)
8/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:KYTX
Previous Symbol
NASDAQ:KYTX
CIK
1994702
Fax
N/A
Employees
96
Year Founded
N/A

Price Target and Rating

High Price Target
$33.00
Low Price Target
$5.00
Potential Upside/Downside
+494.9%
Consensus Rating
Buy
Rating Score (0-4)
3.14
Research Coverage
7 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$127.48 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$7.03 million
Price / Cash Flow
N/A
Book Value
$6.17 per share
Price / Book
0.50

Miscellaneous

Free Float
N/A
Market Cap
$134.41 million
Optionable
Optionable
Beta
2.95
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

This page (NASDAQ:KYTX) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners